Yuchen Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuchen Fu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Yuanyuan Shi
Department of Science and Education, Shenzhen Hospital (Longgang), Beijing University of Chinese Medicine, Shenzhen, China
3 shared publications Qi Ding
2 shared publications- Gonghao Xu
School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China
1 shared publication Minfang Li
Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
1 shared publication- Qi Ding
Central Lab, Beijing University of Chinese Medicine Shenzhen Hospital, Shenzhen, China
1 shared publication - Sheng Chen
Department of Respiratory and Critical Care Medicine, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, China
1 shared publication
Latest Publications
- 27 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 323, 117674
Guben Qingfei decoction attenuates LPS-induced acute lung injury by modulating the TLR4/NF-κB and Keap1/Nrf2 signaling pathways
- 27 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 323, 117674
Guben Qingfei decoction attenuates LPS-induced acute lung injury by modulating the TLR4/NF-κB and Keap1/Nrf2 signaling pathways
- Open Access
- 15 September 2023
- Published by Elsevier in Journal of Functional Foods
- Vol. 109
JBB attenuates acute and chronic alcoholic liver injury by regulating the NFκB, KEAP1, and HIF1 pathways
- 15 September 2023
- Published by Elsevier in Journal of Functional Foods
- Vol. 109
Open AccessJBB attenuates acute and chronic alcoholic liver injury by regulating the NFκB, KEAP1, and HIF1 pathways
- Open Access
- 9 March 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (11) , 10202-10213
Exploring the Mechanism of Bergamot Essential Oil against Asthma Based on Network Pharmacology and Experimental Verification
Asthma is a chronic respiratory disease. Bergamot essential oil (BEO) is extracted from the bergamot peel, which is widely used as a medicinal and food plant in China. Modern pharmacological studies have confirmed that BEO has anti-inflammatory properties, suggesting potential in treating asthma. First, the main active ingredients of BEO were detected and analyzed by gas chromatography-mass spectrometry (GC-MS). Network pharmacology methods were used to explore the possible core targets and main pathways of BEO in asthma treatment. Then ovalbumin (OVA)-induced in vivo and lipopolysaccharide (LPS)-induced in vitro models were established to investigate the antiasthmatic effects of BEO. BEO showed a good antiasthmatic effect by improving lung inflammation and inhibiting collagen deposition. Then, enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qPCR) were used to explore the possible mechanism of BEO in asthma treatment. Furthermore, experimental verification showed that BEO could suppress the release of inflammatory factors in vitro and inhibit the activation of MAPK and JAK-STAT signaling pathways. This study demonstrated the anti-inflammatory effects of BEO against asthma. Moreover, it supplies a theoretical basis for the clinical application of BEO.
- 9 March 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (11) , 10202-10213
Open AccessExploring the Mechanism of Bergamot Essential Oil against Asthma Based on Network Pharmacology and Experimental Verification
Asthma is a chronic respiratory disease. Bergamot essential oil (BEO) is extracted from the bergamot peel, which is widely used as a medicinal and food plant in China. Modern pharmacological studies have confirmed that BEO has anti-inflammatory properties, suggesting potential in treating asthma. First, the main active ingredients of BEO were detected and analyzed by gas chromatography-mass spectrometry (GC-MS). Network pharmacology methods were used to explore the possible core targets and main pathways of BEO in asthma treatment. Then ovalbumin (OVA)-induced in vivo and lipopolysaccharide (LPS)-induced in vitro models were established to investigate the antiasthmatic effects of BEO. BEO showed a good antiasthmatic effect by improving lung inflammation and inhibiting collagen deposition. Then, enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qPCR) were used to explore the possible mechanism of BEO in asthma treatment. Furthermore, experimental verification showed that BEO could suppress the release of inflammatory factors in vitro and inhibit the activation of MAPK and JAK-STAT signaling pathways. This study demonstrated the anti-inflammatory effects of BEO against asthma. Moreover, it supplies a theoretical basis for the clinical application of BEO.